Combined emphysema and cancer, from radiology to prognosis in patients treated by immunotherapy: An ancillary study of a prospective multicenter phase II IFCT-1802 SAVIMMUNE.

Date publication

août 2026

Journal

Respiratory medicine and research

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DEBIEUVRE Didier , Pr WESTEEL Virginie , Pr MASCAUX Céline

Tous les auteurs :
Zysman M, Benlala I, Langlais A, Greillier L, Mascaux C, Pinquie F, Carmier D, Moreau L, Roch B, Debieuvre D, Dhalluin X, Giroux-Leprieur E, Berton E, Duruisseaux M, Raimbourg J, Rabeau A, Dixmier A, Naltet C, Westeel V, Zalcman G, Dournes G, Gounant V

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42696863

Résumé

In studies evaluating the efficacy of anti-programmed cell death (ligand)1 (anti-PD-(L)1) in patients with non-small-cell lung cancer (NSCLC), smokers tend to have better clinical outcomes than non-smokers. However, whether co-existing emphysema is associated with differences in clinical outcomes, regardless of smoking status remains unclear.

Mots clés

Durvalumab, Emphysema, Immune checkpoint inhibitors, NSCLC, Poor performance status

Référence

Respir Med Res. 2026 08 26;90:101317